Open Access Meeting report

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011

Nicolas Ruffin1, Marie Borggren2, Zelda Euler3, Fabio Fiorino4, Katrijn Grupping5, David Hallengärd1, Aneele Javed6, Kevin Mendonca4, Charlotte Pollard5, David Reinhart78, Elisa Saba9, Enas Sheik-Khalil2, Annette Sköld10, Serena Ziglio11, Gabriella Scarlatti12, Frances Gotch13, Britta Wahren1* and Robin J Shattock14

Author Affiliations

1 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Nobels väg 16, Stockholm, 171 77, Sweden

2 Department of Laboratory Medicine, Lund University, Sölvegatan, Lund, 223 62, Sweden

3 Department of Experimental Immunology, Landsteiner Laboratory of Sanquin and the Academic Medical Center, University of Amsterdam, Meibergdreef, Amsterdam, 1105 AZ, The Netherlands

4 Department of Biotechnology, University of Siena, Viale Bracci, Siena, 53100, Italy

5 Institute of Tropical Medicine, Nationalestraat 155, Antwerp, 2000, Belgium

6 Leibniz Institute for Primate Research, German Primate Centre, Kellnerweg, Goettingen, 37077, Germany

7 Polymun Scientific GmbH, Donaustraße 99, 3400, Klosterneuburg, Austria

8 Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 11, 1190, Vienna, Austria

9 AIDS Immunopathogenesis Unit, Department of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, via Olgettina, Milan, 20132, Italy

10 Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge F59, Stockholm, 141 86, Sweden

11 Department of Life and Reproduction Sciences, University of Verona, Strada Le Grazie, Verona, 37134, Italy

12 Viral Evolution and Transmission Unit, Department of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Via Olgettina, Milan, 20132, Italy

13 Department of Immunology, Imperial College London, Fulham Road, London, SW10 9NH, UK

14 Centre for Infection, Department of Clinical Sciences, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK

For all author emails, please log on.

Journal of Translational Medicine 2012, 10:144  doi:10.1186/1479-5876-10-144

Published: 11 July 2012

Abstract

Europrise is a Network of Excellence supported by the European Commission within the 6th Framework programme from 2007 to 2012. The Network has involved over 50 institutions from 13 European countries together with 3 industrial partners and 6 African countries. The Network encompasses an integrated program of research, training, dissemination and advocacy within the field of HIV vaccines and microbicides. A central and timely theme of the Network is the development of the unique concept of co-usage of vaccines and microbicides. Training of PhD students has been a major task, and some of these post-graduate students have here summarized novel ideas emanating from presentations at the last annual Europrise meeting in Prague. The latest data and ideas concerning HIV vaccine and microbicide studies are included in this review; these studies are so recent that the majority have yet to be published. Data were presented and discussed concerning novel immunisation strategies; microbicides and PrEP (alone and in combination with vaccines); mucosal transmission of HIV/SIV; mucosal vaccination; novel adjuvants; neutralizing antibodies; innate immune responses; HIV/SIV pathogenesis and disease progression; new methods and reagents. These – necessarily overlapping topics - are comprehensively summarised by the Europrise students in the context of other recent exciting data.

Keywords:
HIV; Vaccine; Microbicide; PrEP